Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of recombinant human cytoglobin in preparation of drugs treating hyperlipidemia and atherosclerosis

A technology for atherosclerosis and hyperlipidemia, applied in the field of application of recombinant human cytoglobin in the preparation of drugs for treating hyperlipidemia and atherosclerosis

Active Publication Date: 2014-10-15
董文其
View PDF7 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, no literature has reported that human globin can improve or treat hyperlipidemia and atherosclerosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of recombinant human cytoglobin in preparation of drugs treating hyperlipidemia and atherosclerosis
  • Application of recombinant human cytoglobin in preparation of drugs treating hyperlipidemia and atherosclerosis
  • Application of recombinant human cytoglobin in preparation of drugs treating hyperlipidemia and atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0014] 1. Hyperlipidemia rat model test

[0015] 1. Animal modeling:

[0016] Fifty clean-grade healthy adult male SD rats weighing 200-250 g were randomly divided into 2 groups, 10 normal control groups and 40 modeling groups.

[0017] Normal control group: fed ordinary pelleted feed, free food, about 20 grams per animal per day on average.

[0018] Model group: fed with high-fat diet (high-fat diet is a formula selected by the laboratory and produced by the Experimental Animal Center of Southern Medical University: 85% basic diet, 4% cholesterol, 10% lard, 0.2% propylthiouracil, 0.5 % bile salts), free feeding, about 20 grams per animal per day on average. Modeling for 4 weeks.

[0019] After 4 weeks of successful modeling of 40 rats in the modeling group, 10 rats were randomly selected to take blood from the tail vein to measure the four items of blood lipids. The measurement results confirmed that the modeling was successful.

[0020] 2. Animal administration:

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of recombinant human cytoglobin (rhCYGB) in preparation of drugs treating hyperlipidemia and atherosclerosis. A hyperlipidemia rat model and an atherosclerosis rat model are respectively established by the inventor, and subcutaneous injection of rhCYGB is carried out for treatment. Experimental results show that the rhCYGB drug is non-toxic, compared with a model control group, the rhCYGB treatment group has significant improvement, the four items of blood lipid test are significantly decreased than those of a model group, and the four items of blood lipid test of a polysaccharide sulfate treatment group are significantly higher than normal, thus rhCYGB has better efficacy than polysaccharide sulfate in treatment of hyperlipidemia caused by high fat diet. In the atherosclerosis rat model, compared with the model group, the four items of blood lipid test of the treatment group are also significantly reduced, and atherosclerotic plaques also obviously decreased. Therefore, treatment of hyperlipidemia and atherosclerosis by the recombinant human cytoglobin has the advantages of low toxicity, safety and effectiveness.

Description

technical field [0001] The invention relates to a new application of recombinant human cell globin, in particular to the application of recombinant human cell globin in the preparation of drugs for treating hyperlipidemia and atherosclerosis. Background technique [0002] According to relevant reports, hyperlipidemia is closely related to the occurrence and development of atherosclerosis. The main harm of hyperlipidemia is to cause atherosclerosis, which in turn leads to many related diseases, the most common fatal disease is coronary heart disease. Angina pectoris, myocardial infarction, stroke, renal insufficiency, and hemiplegia complicated by atherosclerosis are often the main causes of death in middle-aged and elderly patients. Many doctors believe that effective treatment of hyperlipidemia is very beneficial to prevent the occurrence of atherosclerosis. [0003] Hyperlipidemia is characterized by abnormal fat metabolism or operation, which makes the content of one or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61P3/06A61P9/10
Inventor 董文其欧玲伶魏威李珍王萍
Owner 董文其
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com